Promising antibody therapy aims to calm rare autoimmune disease flare-ups
NCT ID NCT06940661
First seen Apr 12, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This study tests a drug called obinutuzumab in 33 adults with a relapsing form of a rare autoimmune disease that inflames blood vessels (PR3-ANCA granulomatosis with polyangiitis). The goal is to see if the drug can stop disease activity and normalize blood markers within 6 months, while safely reducing steroid use. Participants receive the drug intravenously and are monitored for side effects and remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRANULOMATOSIS WITH POLYANGIITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Service de Médecine Interne, Centre de reference "Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques"
RECRUITINGParis, 75014, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.